Unlocking the full potential of cancer treatments using targeted radionuclide therapy through Netherlands-UK partnerships.
Investigating the optimal use of radioactive cancer-targeted drugs presents a unique opportunity to improve cancer treatment, by personalising it to an individual's needs, treating cancer that is spread throughout the body, or has become resistant to other therapies. By combining the strengths of the UK and Netherlands in science and health technologies and prioritising funding towards this research area, there is now the opportunity to accelerate research into optimising these radioactive drugs, and for both nations to maintain global leadership in this field.
This white paper outlines three strategic recommendations to achieve this ambition:
- Strategically allocate funding to enhance mechanistic understanding of targeted radioactive drugs.
- Facilitate UK-NL clinical trials in targeted radionuclide therapies.
- Coordinate training initiatives.
To read the entire paper, download it now:
Endorse our white paper
We are collecting endorsements to demonstrate to policymakers and funders alike that targeted radionuclide therapy is a crucial area of research that requires investment. To register your support, please complete the form below and leave a short message of recommendation in the 'Endorsement' field.
Please note that by leaving an endorsement, you are giving us permission to share your message both publicly and privately with policymakers, funders and other parties. Endorsements are optional.
You can opt in to receive updates on our progress, future meetings, funding calls and other information about this project by checking the 'Yes' box below.
If you check the 'No' box, we will still collect your email for your endorsement only, but will not send you any updates.
Julie Nonnekens (Erasmus MC Rotterdam, the Netherlands) and Samantha Terry (King’s College London, UK) would like to thank and acknowledge input from:
Steve Archibald, King’s College London, UK
Sean Collins, National Physical Laboratory, UK
Bart Cornelissen, UMC Groningen, the Netherlands
Mark Gaze, University College London, UK
Wim Oyen, Rijnstate Hospital Arnhem, the Netherlands
Mark Konijnenberg, Erasmus MC Rotterdam, the Netherlands
Daphne Lobeek, Radboud UMC, the Netherlands
Edward O’Neill, Oxford University, UK
Steffie Peters, Radboud UMC, the Netherlands
Giuseppe Schettino, National Physical Laboratory, UK
Jane Sosabowski, Queen Mary University of London, UK
Tim Smith, Bangor University, University of Manchester, UK
Alexander Turkin, Oncode Institute, the Netherlands
Katherine Vallis, Oxford University, UK
Jennifer Young, King’s College London, UK
